Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$0.26
-3.8%
C$0.26
C$0.15
C$0.53
C$52.28MN/A644,760 shs384,329 shs
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$10.70
$10.70
$3.95
$11.35
$292.42M2.38327,575 shs54 shs
Hemostemix Inc. stock logo
HEM
Hemostemix
C$0.09
+12.5%
C$0.10
C$0.04
C$0.43
C$13.12M0.2488,498 shs316,000 shs
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
$0.50
+5.1%
$0.58
$0.47
$2.37
$16.50M0.0276,597 shs24,198 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00%0.00%0.00%0.00%0.00%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00%0.00%0.00%0.00%0.00%
Hemostemix Inc. stock logo
HEM
Hemostemix
+12.50%-18.18%-5.26%-50.00%+125.00%
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
+5.13%-1.83%-13.45%-31.16%-72.58%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
3.174 of 5 stars
3.55.00.00.03.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00
N/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00
N/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
0.00
N/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
3.00
Buy$4.50791.80% Upside

Current Analyst Ratings Breakdown

Latest HEM, EMH, PMN, and HBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/1/2025
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$937.80M0.31$1.97 per share5.43$3.40 per share3.15
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AC$0.01 per share10.77C($0.10) per shareN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A-C$0.70N/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$48.50M$1.776.05N/A5.17%66.00%15.67%N/A
Hemostemix Inc. stock logo
HEM
Hemostemix
-C$5.00M-C$0.03N/AN/AN/A37.07%-349.24%N/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$13.21M-$0.05N/AN/AN/AN/A-636.20%-130.32%8/14/2025 (Estimated)

Latest HEM, EMH, PMN, and HBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$0.14-$0.21-$0.07-$0.21N/AN/A
3/31/2025Q4 2024
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
-$0.14-$0.02+$0.12-$0.02N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
35.45
2.97
2.61
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.75
2.05
0.95
Hemostemix Inc. stock logo
HEM
Hemostemix
-55.07
0.04
0.48
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
N/A
9.30
9.30

Institutional Ownership

CompanyInstitutional Ownership
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
54.10%
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
50.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
161205.03 millionN/ANot Optionable
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
1,10027.33 million24.34 millionOptionable
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A145.73 millionN/ANot Optionable
ProMIS Neurosciences, Inc. stock logo
PMN
ProMIS Neurosciences
532.69 million31.25 millionNot Optionable

Recent News About These Companies

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial
ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Emerald Health Therapeutics stock logo

Emerald Health Therapeutics CVE:EMH

C$0.26 -0.01 (-3.77%)
As of 04/26/2021

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

Huttig Building Products stock logo

Huttig Building Products NASDAQ:HBP

Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.

Hemostemix stock logo

Hemostemix CVE:HEM

C$0.09 +0.01 (+12.50%)
As of 05/29/2025 12:20 PM Eastern

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

ProMIS Neurosciences stock logo

ProMIS Neurosciences NASDAQ:PMN

$0.50 +0.02 (+5.13%)
Closing price 05/29/2025 03:47 PM Eastern
Extended Trading
$0.50 +0.00 (+0.08%)
As of 05/29/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.